Drug intelligence / Profile preview

SYR-619

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

SYR-619 is an oral small molecule drug developed as a dipeptidyl peptidase 4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors work by blocking the enzyme dipeptidyl peptidase IV, which increases levels of incretin hormones, thereby enhancing insulin secretion and lowering blood glucose. The drug was originally developed by Syrrx, which was later acquired and renamed Takeda San Diego. Development reached phase 2 clinical trials but was ultimately discontinued for type 2 diabetes[1][2][3][4].

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on SYR-619.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYR-619.

Explore the full profile